Celldex Depreciation And Amortization vs Reconciled Depreciation Analysis

CLDX Stock  USD 26.70  0.31  1.15%   
Celldex Therapeutics financial indicator trend analysis is way more than just evaluating Celldex Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Celldex Therapeutics is a good investment. Please check the relationship between Celldex Therapeutics Depreciation And Amortization and its Reconciled Depreciation accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.

Depreciation And Amortization vs Reconciled Depreciation

Depreciation And Amortization vs Reconciled Depreciation Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Celldex Therapeutics Depreciation And Amortization account and Reconciled Depreciation. At this time, the significance of the direction appears to have weak contrarian relationship.
The correlation between Celldex Therapeutics' Depreciation And Amortization and Reconciled Depreciation is -0.13. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Reconciled Depreciation in the same time period over historical financial statements of Celldex Therapeutics, assuming nothing else is changed. The correlation between historical values of Celldex Therapeutics' Depreciation And Amortization and Reconciled Depreciation is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Celldex Therapeutics are associated (or correlated) with its Reconciled Depreciation. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Reconciled Depreciation has no effect on the direction of Depreciation And Amortization i.e., Celldex Therapeutics' Depreciation And Amortization and Reconciled Depreciation go up and down completely randomly.

Correlation Coefficient

-0.13
Relationship DirectionNegative 
Relationship StrengthInsignificant

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Reconciled Depreciation

Most indicators from Celldex Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Celldex Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Celldex Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
For more information on how to buy Celldex Stock please use our How to Invest in Celldex Therapeutics guide.At this time, Celldex Therapeutics' Tax Provision is fairly stable compared to the past year. Enterprise Value is likely to rise to about 1.8 B in 2024, whereas Selling General Administrative is likely to drop slightly above 29.4 M in 2024.
 2023 2024 (projected)
Extraordinary Items17.2M15.3M
Reconciled Depreciation2.9M3.1M

Celldex Therapeutics fundamental ratios Correlations

0.750.790.980.28-0.43-0.670.390.210.940.690.120.420.80.330.830.940.36-0.040.140.73-0.270.030.390.390.19
0.750.670.690.29-0.34-0.460.30.360.630.480.370.290.560.480.590.630.45-0.03-0.010.59-0.10.00.30.30.52
0.790.670.70.71-0.29-0.380.280.510.620.270.440.360.490.660.510.620.410.350.060.610.060.360.670.670.47
0.980.690.70.16-0.43-0.690.40.050.980.76-0.050.40.820.160.870.980.31-0.170.20.75-0.32-0.070.270.270.03
0.280.290.710.16-0.380.230.410.630.06-0.420.60.1-0.150.73-0.10.060.080.64-0.080.110.370.60.750.750.53
-0.43-0.34-0.29-0.43-0.38-0.07-0.99-0.05-0.420.060.020.02-0.05-0.09-0.05-0.420.030.05-0.07-0.230.30.13-0.39-0.390.03
-0.67-0.46-0.38-0.690.23-0.070.11-0.05-0.65-0.870.04-0.51-0.98-0.06-0.75-0.66-0.60.210.22-0.560.330.130.220.22-0.08
0.390.30.280.40.41-0.990.110.050.38-0.1-0.02-0.040.010.090.010.38-0.07-0.050.090.18-0.21-0.050.390.39-0.05
0.210.360.510.050.63-0.05-0.050.05-0.14-0.260.960.180.040.95-0.1-0.130.290.68-0.25-0.050.230.560.670.670.87
0.940.630.620.980.06-0.42-0.650.38-0.140.78-0.220.350.79-0.010.871.00.25-0.280.240.75-0.36-0.170.160.16-0.12
0.690.480.270.76-0.420.06-0.87-0.1-0.260.78-0.330.420.9-0.220.90.790.33-0.520.140.66-0.31-0.27-0.28-0.28-0.19
0.120.370.44-0.050.60.020.04-0.020.96-0.22-0.330.16-0.060.96-0.18-0.220.240.7-0.34-0.160.230.490.620.610.95
0.420.290.360.40.10.02-0.51-0.040.180.350.420.160.490.260.530.370.160.19-0.20.57-0.170.020.070.070.22
0.80.560.490.82-0.15-0.05-0.980.010.040.790.9-0.060.490.080.830.790.57-0.22-0.110.66-0.34-0.13-0.11-0.110.06
0.330.480.660.160.73-0.09-0.060.090.95-0.01-0.220.960.260.08-0.010.00.280.7-0.270.040.210.530.720.720.91
0.830.590.510.87-0.1-0.05-0.750.01-0.10.870.9-0.180.530.83-0.010.880.2-0.350.310.77-0.16-0.07-0.010.0-0.06
0.940.630.620.980.06-0.42-0.660.38-0.131.00.79-0.220.370.790.00.880.26-0.280.230.75-0.36-0.170.160.16-0.11
0.360.450.410.310.080.03-0.6-0.070.290.250.330.240.160.570.280.20.260.28-0.510.33-0.20.08-0.03-0.020.29
-0.04-0.030.35-0.170.640.050.21-0.050.68-0.28-0.520.70.19-0.220.7-0.35-0.280.28-0.47-0.150.060.450.550.550.59
0.14-0.010.060.2-0.08-0.070.220.09-0.250.240.14-0.34-0.2-0.11-0.270.310.23-0.51-0.470.30.1-0.060.260.27-0.43
0.730.590.610.750.11-0.23-0.560.18-0.050.750.66-0.160.570.660.040.770.750.33-0.150.3-0.32-0.240.190.2-0.06
-0.27-0.10.06-0.320.370.30.33-0.210.23-0.36-0.310.23-0.17-0.340.21-0.16-0.36-0.20.060.1-0.320.80.070.060.19
0.030.00.36-0.070.60.130.13-0.050.56-0.17-0.270.490.02-0.130.53-0.07-0.170.080.45-0.06-0.240.80.390.390.36
0.390.30.670.270.75-0.390.220.390.670.16-0.280.620.07-0.110.72-0.010.16-0.030.550.260.190.070.391.00.45
0.390.30.670.270.75-0.390.220.390.670.16-0.280.610.07-0.110.720.00.16-0.020.550.270.20.060.391.00.45
0.190.520.470.030.530.03-0.08-0.050.87-0.12-0.190.950.220.060.91-0.06-0.110.290.59-0.43-0.060.190.360.450.45
Click cells to compare fundamentals

Celldex Therapeutics Account Relationship Matchups

Celldex Therapeutics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets122.9M235.8M444.7M352.7M465.6M488.9M
Other Current Liab2.0M10.5M11.8M12.4M24.4M25.6M
Total Current Liabilities11.6M14.2M16.5M18.6M31.1M32.7M
Total Stockholder Equity94.0M209.4M419.5M326.2M429.2M450.6M
Property Plant And Equipment Net4.0M3.8M3.6M3.7M6.6M5.7M
Net Debt(7.6M)(40.4M)(36.1M)(25.4M)(32.3M)(33.9M)
Retained Earnings(1.0B)(1.1B)(1.1B)(1.3B)(1.4B)(1.3B)
Cash11.2M43.8M39.1M29.4M34.8M31.5M
Non Current Assets Total56.2M38.0M33.8M35.0M33.9M31.0M
Cash And Short Term Investments64.4M194.4M408.3M305.0M423.6M444.8M
Common Stock Shares Outstanding14.5M29.6M42.9M46.9M48.4M50.9M
Liabilities And Stockholders Equity122.9M235.8M444.7M352.7M465.6M488.9M
Non Current Liabilities Total17.3M12.3M8.7M7.9M5.3M5.1M
Other Current Assets2.3M1.6M2.4M12.4M5.5M2.8M
Other Stockholder Equity1.1B1.3B1.6B1.6B1.8B1.9B
Total Liab28.9M26.5M25.2M26.5M36.5M25.7M
Property Plant And Equipment Gross7.5M7.3M27.6M29.4M29.0M30.5M
Total Current Assets66.7M197.8M410.8M317.7M431.7M453.3M
Accumulated Other Comprehensive Income2.6M2.6M1.9M1.3M3.3M3.5M
Net Receivables1.0M1.8M172K347K2.6M2.8M
Inventory(1.0M)(1.8M)(172K)(347K)1.00.95
Accounts Payable1.2M1.0M1.2M3.3M3.5M3.7M
Short Long Term Debt Total3.7M3.5M3.0M4.0M2.5M4.6M
Short Term Debt1.9M2.7M3.5M2.9M3.2M2.9M
Common Stock Total Equity12K17K40K47K54.1K65.1K
Common Stock12K17K40K47K56K64.5K
Intangible Assets52.2M34.2M30.3M31.3M27.2M34.2M
Current Deferred Revenue2.5M6.5M8.5M12M10.8M10.3M
Other Liab15.6M10.1M7.4M5.3M6.1M5.8M
Property Plant Equipment4.0M7.3M6.5M7.7M7.0M7.2M
Short Term Investments53.2M150.6M369.1M275.5M388.8M408.2M
Net Tangible Assets45.3M178.7M392.3M299.0M343.9M361.1M
Retained Earnings Total Equity(962.4M)(1.0B)(1.1B)(1.1B)(1.0B)(1.1B)
Capital Surpluse1.1B1.1B1.3B1.6B1.8B1.0B
Non Current Liabilities Other17.3M10.1M7.4M5.3M4.4M4.2M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Celldex Stock Analysis

When running Celldex Therapeutics' price analysis, check to measure Celldex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Celldex Therapeutics is operating at the current time. Most of Celldex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Celldex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Celldex Therapeutics' price. Additionally, you may evaluate how the addition of Celldex Therapeutics to your portfolios can decrease your overall portfolio volatility.